CNS Pharmaceuticals SEC filings document the regulatory record for a clinical-stage pharmaceutical company developing therapies for brain and central nervous system cancers. Its filings cover material-event reports, Regulation FD investor presentations, operating and financial updates, clinical and regulatory disclosures, and capital-structure information for its Nasdaq-listed common stock.
The company’s proxy and 8-K filings also describe governance matters, annual-meeting votes, equity-plan amendments, officer appointments, employment agreements and related compensation arrangements. These disclosures frame the company’s formal reporting around pipeline strategy, corporate leadership, stockholder approvals and public-company controls.
CNS Pharmaceuticals, Inc. (CNSP) reported that stockholders approved an amendment adding 650,000 shares to the 2020 Equity Plan; the amended plan permits issuance of 765,061 shares in total, including the increase. The vote took place at the September 30, 2026 annual meeting.
Stockholders elected Faith Charles, Bettina Cockroft, Michal Fisher, Jeffrey Keyes, Rami Levin and Amy Mahery through the 2027 annual meeting, ratified MaloneBailey, LLP as the independent registered public accounting firm for the year ending December 31, 2026, and approved executive compensation on an advisory basis. Stockholders also authorized adjournment, if necessary, to solicit additional proxies when votes were insufficient on the proposals.
CNS Pharmaceuticals, Inc. (CNSP) is soliciting proxies for its 2026 virtual annual meeting of stockholders, to be held on September 30, 2026 at 12:00 P.M. Eastern. Stockholders of record at the close of business on August 10, 2026 may vote; there were 1,461,449 shares of common stock outstanding on that date.
Stockholders will vote on: electing six directors; ratifying MaloneBailey, LLP as independent auditor for 2026; a non-binding advisory vote on executive compensation; amendments to the 2020 Stock Plan, including an increase of 650,000 shares authorized for issuance under the plan; and potential adjournment to solicit additional proxies. The proxy describes board structure, committee independence, detailed executive and director compensation, change-in-leadership arrangements, and ownership data, including two investors reported at 9.9% and 5.7% beneficial ownership based on recent Schedule 13G filings.
CNS Pharmaceuticals, Inc. director Michal Fisher reported an open-market purchase of company stock. On May 18, 2026, Fisher purchased 2,000 shares of CNSP common stock at $5.00 per share. Following this transaction, Fisher directly holds 2,000 common shares of the company.
CNS Pharmaceuticals, Inc. filed an initial statement of beneficial ownership on Form 3 for Fisher Michal, who is identified as a director of the company. The filing notes an attached Power of Attorney, authorizing representation in securities reporting matters. No specific transactions are reported.
Levin Rami reported disposition transactions in this Form 4 filing.
CNS Pharmaceuticals, Inc. executive Rami Levin reported the vesting and conversion of 4,750 Restricted Stock Units into 4,750 shares of Common Stock on August 14, 2026. Each RSU represents a contingent right to one share of common stock. The RSUs stem from a 19,000-unit grant made on January 1, 2026, which vests 25% at six months, 25% at twelve months, and the remaining 50% in twelve quarterly installments, subject to continued employment. Following this transaction, Levin holds 14,250 RSUs and 4,750 shares of Common Stock directly, and the filing indicates these transactions were not made under a Rule 10b5-1 trading plan.
Ikarian Capital, LLC and Neil Shahrestani report beneficial ownership of 147,290 shares of CNS Pharmaceuticals, Inc. common stock, including 11,460 shares issuable upon exercise of warrants that are subject to a 9.99% Beneficial Ownership Limitation. Based on 1,472,909 shares deemed outstanding, they report owning 9.9% of the common stock. The shares are held by Ikarian Healthcare Master Fund, L.P. and certain separately managed accounts over which Ikarian Capital has investment discretion. The reporting persons expressly disclaim being part of a group or being beneficial owners for certain legal purposes, despite potentially being deemed so under Section 13(d) or 13(g).
CNS Pharmaceuticals, Inc. reported interim results for the three and six months ended June 30, 2026, reflecting its pivot to a broader pipeline strategy while remaining pre-revenue and loss-making. Total assets rose to $21.9 million from $8.6 million at year-end 2025, driven mainly by a cash balance of about $20.0 million following a May 2026 private placement and use of its at-the-market program.
The company recorded a net loss of about $2.6 million for the quarter and $7.5 million for the first half, compared with $2.4 million and $6.7 million in the prior-year periods, as research and development and general and administrative expenses both increased. As of June 30, 2026, accumulated deficit reached $107.8 million, but management states existing cash plus net proceeds from recent financings are expected to fund planned operations for more than twelve months from issuance of these financial statements.
CNS completed a $22.5 million gross private placement, issuing 650,000 common shares and pre-funded warrants for 9,143,479 shares, and sold additional stock via its AGP ATM program. It reported material weaknesses in internal control over financial reporting, including segregation-of-duties limitations and reliance on a contract research organization, and disclosed these controls remain ineffective as of June 30, 2026.
CNS Pharmaceuticals, Inc. used this report to share an updated investor presentation describing a major strategic pivot and recent financing. The company is shifting its focus toward high‑value oncology and neurology markets, targeting novel, differentiated assets with clear development pathways and near‑term clinical or regulatory milestones.
The presentation highlights a $22.5 million private placement completed in May 2026, described as a top‑performing PIPE for the first half of 2026. The deal included 650,000 common shares and 9,143,479 pre‑funded warrants, providing capital to acquire clinical‑stage assets and pursue an asset‑in‑licensing strategy. As of June 30, 2026, common stock outstanding was 1,461,449 shares, and assuming exercise of all pre‑funded warrants, the pro forma fully diluted market capitalization is presented as approximately $50.7 million.
Management emphasizes a purpose‑built executive team with deep experience in oncology, neurology and rare diseases, and outlines plans to out‑license legacy glioblastoma programs while searching globally for underfunded or shelved clinical‑stage assets. The capital structure is described as clean, with no debt, preferred or convertible securities, and pre‑funded warrants subject to 4.99% and 9.99% beneficial ownership caps.
CNS Pharmaceuticals, Inc. registers up to 9,793,479 shares of common stock for resale by selling shareholders under a prospectus dated May 26, 2026.
The registration covers (i) 650,000 shares issued in a private placement and (ii) 9,143,479 shares issuable upon exercise of Pre-Funded Warrants exercisable at $0.001 per share. The company will not receive proceeds from resale; it received gross proceeds of approximately $22.5 million in the Private Placement.